[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fetal-anemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fetal-anemia":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,36,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100635326","evaluation-of-myocardial-performance-index-in-cases-of-fetal-anemia-a-prospective-study-100635326",false,"NCT07551232","Evaluation of Myocardial Performance Index in Cases of Fetal Anemia: A Prospective Study","Inclusion Criteria:Singleton pregnancy with raised MCA PSV MOM due to alloimmunization or Parvovirus infection will be invited to participate in the study.Institutional ethics committee approval will be gained and all women who participate in the study will gave an informed consent.\n\n\\-\n\nExclusion Criteria:fetuses with structural or chromosomal anomalies, maternal systemic diseases (e.g., cardiac disease, respiratory disease, sever maternal coagulopathy),and cases in which technically reliable Mod-MPI measurements could not be obtained as obese women.. Active maternal infection at puncture site.\n\n\\-","FEMALE",{"count":17,"type":18},15,"ESTIMATED","OBSERVATIONAL","To Evaluation of myocardial performance index in cases of fetal anemia",[22,23],"Fetal Anemia","Fetal Echocardiography","NOT_YET_RECRUITING","2026-04-20",{"date":27,"type":28},"2026-04-24","ACTUAL",{"date":30,"type":18},"2026-05-01",{"date":32,"type":18},"2028-05-01",{"name":34,"class":35},"Assiut University","OTHER",{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":4,"eligibilityCriteria":41,"healthyVolunteers":42,"sex":15,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100624463","middle-cerebral-artery-acceleration-time-as-indicator-in-fetal-anemia-100624463","NCT07409961","Middle Cerebral Artery Acceleration Time as Indicator in Fetal Anemia","Inclusion Criteria:\n\n* fetus with fetal anemia or hyperdynamic state\n\nExclusion Criteria:\n\n* associated fetal congenital anomalies",true,"18 Years","35 Years",{"count":46,"type":18},20,"Fetal anemia one of serious fetal problems that may lead in sever cases to fetal demise early detection and precise intervention safe fetal life , traditional evaluation the severity and need of blood transfusion done by middle cerebral artery peak systolic velocity in doppler wave, in this study innovative technique suggested to compared with standard technique",[22],"2026-02-07",{"date":51,"type":28},"2026-02-13",{"date":53,"type":18},"2026-03-01",{"date":55,"type":18},"2027-06-01",{"name":34,"class":35},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":43,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100591747","cord-blood-s100b-protein-levels-in-neonates-following-intrauterine-transfusions-for-hdfn-associated-fetal-anemia-100591747","NCT06984445","Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia","Analysis of Cord Blood S100B Protein Levels in Neonates With Fetal Anemia Due to Hemolytic Disease Undergoing Intrauterine Transfusions: A Prospective Cohort Study","Study Group - Inclusion Criteria:\n\n1. Singleton pregnancy.\n2. Diagnosis of HDFN confirmed by the detection of alloantibodies through maternal blood screening.\n3. Availability of complete medical records, including routine ultrasound assessments of fetal MCA blood flow.\n4. Fetal anemia requiring IUT, indicated by a MCA-PSV MoM value exceeding 1.5.\n\nStudy Group - Exclusion Criteria:\n\n1\\. Maternal chronic use of selective serotonin reuptake inhibitors (SSRIs).\n\nControl Group - Inclusion Criteria:\n\n1. Singleton pregnancy.\n2. Diagnosis of HDFN confirmed by the detection of alloantibodies through maternal blood screening.\n3. Availability of complete medical records, including routine ultrasound assessments of fetal MCA blood flow.\n4. No indications for IUT, as determined by MCA-PSV MoM values \\\u003C1.5 in routine assessments of fetal cerebral arterial flow.\n\nControl Group - Exclusion Criteria:\n\n1\\. Maternal chronic use of selective serotonin reuptake inhibitors (SSRIs).",{"count":65,"type":18},180,"levated levels of S100B protein are a well-established marker of central nervous system (CNS) damage. Fetal anemia resulting from hemolytic disease of the fetus and newborn (HDFN) often necessitates intrauterine transfusions (IUTs) and represents a significant risk factor for CNS injury. However, it remains uncertain whether S100B protein levels can reliably predict which fetuses are at higher risk for CNS complications in this context. Furthermore, the potential role of measuring S100B concentrations before IUT in prenatal assessments, and its relationship to the severity of anemia and fetal cerebral blood flow, remains poorly understood. This study aims to investigate the concentration of S100B protein in cord blood from newborns with HDFN-related fetal anemia requiring IUT. The study group comprises pregnancies complicated by HDFN with abnormal middle cerebral artery (MCA) blood flow, indicating the need for IUT. In this group, S100B protein levels will be measured before each IUT, with additional measurements if further transfusions are required. The control group consists of pregnancies with HDFN that do not require IUT. Cord blood samples will be collected at birth to evaluate S100B protein levels in both groups. Additionally, fetal MCA blood flow will be monitored, and in the study group, fetal hemoglobin and hematocrit levels will be assessed before each IUT. The primary endpoints of the study include the measurement of cord blood S100B protein levels before IUT in the study group and at birth in both groups. Secondary endpoints will explore the potential correlations between S100B protein levels and umbilical cord blood gas parameters (e.g., pH, BE, lactate), fetal cerebral blood flow parameters (e.g., MCA-PSV values), and blood count parameters (e.g., hemoglobin and hematocrit levels), both before IUT in the study group and after birth in both groups.",[68,69,70,22],"s100b","Hypoxia-Ischemia, Brain","Hemolytic Disease of the Fetus and Newborn",[72,73,74,75,76,77,78],"S100B protein","hemolytic disease of fetus and newborn (HDFN)","intrauterine transfusion (IUT)","fetal anemia","newborn","central nervous system (CNS) damage","CNS hypoxia-ischemia (HI)","RECRUITING","2025-05-14",{"date":82,"type":28},"2025-05-22",{"date":84,"type":28},"2024-07-17",{"date":86,"type":18},"2026-04-30",{"name":88,"class":35},"Institute of Mother and Child, Warsaw, Poland",1]